- Home
- NVRO vs KOD Comparison
NVRO vs KOD Comparison
Compare NVRO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRO
- KOD
- Stock Information
- Founded
- NVRO 2006
- KOD 2009
- Country
- NVRO United States
- KOD United States
- Employees
- NVRO N/A
- KOD N/A
- Industry
- NVRO Medical/Dental Instruments
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVRO Health Care
- KOD Health Care
- Exchange
- NVRO Nasdaq
- KOD Nasdaq
- Market Cap
- NVRO 221.2M
- KOD 191.6M
- IPO Year
- NVRO 2014
- KOD 2018
- Fundamental
- Price
- NVRO $5.85
- KOD $2.56
- Analyst Decision
- NVRO Hold
- KOD Hold
- Analyst Count
- NVRO 12
- KOD 4
- Target Price
- NVRO $7.24
- KOD $8.00
- AVG Volume (30 Days)
- NVRO 1.3M
- KOD 359.1K
- Earning Date
- NVRO 03-04-2025
- KOD 03-27-2025
- Dividend Yield
- NVRO N/A
- KOD N/A
- EPS Growth
- NVRO N/A
- KOD N/A
- EPS
- NVRO N/A
- KOD N/A
- Revenue
- NVRO $408,518,000.00
- KOD N/A
- Revenue This Year
- NVRO $1.55
- KOD N/A
- Revenue Next Year
- NVRO $4.36
- KOD N/A
- P/E Ratio
- NVRO N/A
- KOD N/A
- Revenue Growth
- NVRO N/A
- KOD N/A
- 52 Week Low
- NVRO $3.17
- KOD $2.19
- 52 Week High
- NVRO $13.84
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- NVRO 70.38
- KOD 26.81
- Support Level
- NVRO $5.83
- KOD $2.97
- Resistance Level
- NVRO $5.81
- KOD $3.59
- Average True Range (ATR)
- NVRO 0.02
- KOD 0.27
- MACD
- NVRO -0.02
- KOD 0.02
- Stochastic Oscillator
- NVRO 95.00
- KOD 0.00
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.